DK0490689T3 - 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indol-5-methansulfonamid sulfatsalt (2:1) - Google Patents

3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indol-5-methansulfonamid sulfatsalt (2:1)

Info

Publication number
DK0490689T3
DK0490689T3 DK91311583.8T DK91311583T DK0490689T3 DK 0490689 T3 DK0490689 T3 DK 0490689T3 DK 91311583 T DK91311583 T DK 91311583T DK 0490689 T3 DK0490689 T3 DK 0490689T3
Authority
DK
Denmark
Prior art keywords
indole
dimethylamino
ethyl
methyl
sulfate salt
Prior art date
Application number
DK91311583.8T
Other languages
English (en)
Inventor
Joanne Craig
Derek Leslie Crookes
Stephen John Skittrall
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0490689T3 publication Critical patent/DK0490689T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
DK91311583.8T 1990-12-12 1991-12-12 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indol-5-methansulfonamid sulfatsalt (2:1) DK0490689T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909026998A GB9026998D0 (en) 1990-12-12 1990-12-12 Medicaments

Publications (1)

Publication Number Publication Date
DK0490689T3 true DK0490689T3 (da) 1995-05-22

Family

ID=10686904

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91311583.8T DK0490689T3 (da) 1990-12-12 1991-12-12 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indol-5-methansulfonamid sulfatsalt (2:1)

Country Status (36)

Country Link
US (2) US5554639A (da)
EP (1) EP0490689B1 (da)
JP (1) JP2994037B2 (da)
KR (1) KR100211479B1 (da)
CN (2) CN1030890C (da)
AP (1) AP230A (da)
AT (1) ATE119881T1 (da)
AU (1) AU650706B2 (da)
BE (1) BE1005085A3 (da)
CA (1) CA2098302C (da)
CH (1) CH684192A5 (da)
CY (1) CY2005A (da)
CZ (1) CZ281931B6 (da)
DE (1) DE69108200T2 (da)
DK (1) DK0490689T3 (da)
EG (1) EG20219A (da)
ES (1) ES2069836T3 (da)
FR (1) FR2670487B1 (da)
GB (2) GB9026998D0 (da)
GR (1) GR3015430T3 (da)
HK (1) HK82697A (da)
HU (1) HU211937A9 (da)
IE (1) IE62894B1 (da)
IL (1) IL100330A (da)
IS (1) IS1706B (da)
IT (1) IT1252868B (da)
MX (1) MX9102501A (da)
MY (1) MY109265A (da)
NL (1) NL9102071A (da)
NZ (1) NZ240942A (da)
PT (1) PT99757B (da)
RU (1) RU2108328C1 (da)
TW (2) TW205035B (da)
WO (1) WO1992010477A1 (da)
YU (1) YU48926B (da)
ZA (1) ZA919750B (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0573221T3 (da) * 1992-06-05 1998-10-07 Merck Sharp & Dohme Sulfatsaltet af en substitueret triazol, farmaceutiske præparater deraf og deres anvendelse i terapi
FR2749846B1 (fr) * 1996-06-17 1998-09-11 Pf Medicament Sel de methanesulfonate d'une arylpiperazine derivee de tryptamine et ses solvates pour usage pharmaceutique
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6106837A (en) * 1997-05-15 2000-08-22 Hirsch; Alan R. Method of treating headaches, and article of manufacture therefor
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
GB9926250D0 (en) * 1999-11-06 2000-01-12 Knoll Ag Chemical process
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6562838B2 (en) * 2001-01-26 2003-05-13 R. T. Alamo Ventures I, L.L.C. Treatment of cardiovascular disease with quinolinone enantiomers
US6458804B1 (en) 2001-01-26 2002-10-01 R.T. Alamo Venturesi, Llc Methods for the treatment of central nervous system disorders in certain patient groups
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US20030096748A1 (en) * 2001-06-04 2003-05-22 The Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20030013753A1 (en) * 2001-06-05 2003-01-16 Ronald Aung-Din Transdermal migraine therapy
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
US7208628B2 (en) * 2002-05-13 2007-04-24 Kansas State University Research Foundation Compositions and methods for the treatment of hepatitis C virus infection
US7074893B2 (en) * 2002-06-03 2006-07-11 Regents Of The University Of Michigan Methods and compositions for the treatment of diseases associated with signal transduction aberrations
US20040068000A1 (en) * 2002-10-02 2004-04-08 Mintong Guo Compression coated tablets
AU2003303631B2 (en) * 2002-12-26 2008-05-29 Nuvo Pharmaceuticals (Ireland) Designated Activity Company Multilayer Dosage Forms Containing NSAIDs and Triptans
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004076403A1 (en) * 2003-02-24 2004-09-10 Transform Pharmaceuticals, Inc. Sumatriptan crystalline forms, pharmaceutical compositions and methods
CA2529528A1 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20050089558A1 (en) * 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
WO2005119607A2 (en) * 2004-06-03 2005-12-15 Tyfone, Inc. System and method for securing financial transactions
CA2569964A1 (en) * 2004-06-10 2005-12-29 Duramed Pharmaceuticals, Inc. Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AU2006249577A1 (en) 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
AR058389A1 (es) 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
AU2007253814A1 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
PL2124556T3 (pl) 2006-10-09 2015-02-27 Charleston Laboratories Inc Kompozycje farmaceutyczne
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
GB2448183A (en) * 2007-04-05 2008-10-08 Optinose As Nasal powder delivery device
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20090252791A1 (en) * 2008-04-02 2009-10-08 Venkata Nookaraju Sreedharala Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug
AU2009253738B2 (en) 2008-05-27 2012-12-13 Biota Scientific Management Pty Ltd Antiviral salts
EP2306998A4 (en) * 2008-06-20 2011-06-15 Alphapharm Pty Ltd PHARMACEUTICAL FORMULATION
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
WO2010005507A1 (en) * 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
US9211282B2 (en) 2009-09-25 2015-12-15 Dr. Reddy's Laboratories Ltd. Formulations comprising triptan compounds
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
WO2016187013A1 (en) 2015-05-15 2016-11-24 The Regents Of The University Of Michigan Methods and compositions for the treatment of arthritis
EP3423041A4 (en) 2016-03-04 2019-09-11 Charleston Laboratories, Inc. PHARMACEUTICAL COMPOSITIONS
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
AU2018366022A1 (en) 2017-11-07 2020-04-30 The Regents Of The University Of Michigan Small molecule inhibitors of shared epitope-calreticulin interactions and methods of use
US20220096438A1 (en) 2018-09-07 2022-03-31 Upsher-Smith Laboratories, Llc Methods of treating migraine
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
CN115335051A (zh) * 2020-02-27 2022-11-11 拜尔哈文制药股份有限公司 瑞美吉泮的口服快速分散型剂型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
GB8615599D0 (en) * 1986-06-26 1986-07-30 Glaxo Group Ltd Chemical compounds
GB8928208D0 (en) * 1989-12-13 1990-02-14 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
PT99757B (pt) 1999-05-31
CA2098302C (en) 2001-10-16
CN1030890C (zh) 1996-02-07
CN1063099A (zh) 1992-07-29
GB2251614A (en) 1992-07-15
IT1252868B (it) 1995-06-28
US5705520A (en) 1998-01-06
KR100211479B1 (ko) 1999-08-02
HU211937A9 (en) 1996-01-29
EP0490689B1 (en) 1995-03-15
MX9102501A (es) 1992-09-01
MY109265A (en) 1996-12-31
RU2108328C1 (ru) 1998-04-10
YU48926B (sh) 2002-12-10
EP0490689A1 (en) 1992-06-17
GR3015430T3 (en) 1995-06-30
IL100330A (en) 1996-06-18
IL100330A0 (en) 1992-09-06
US5554639A (en) 1996-09-10
CN1050831C (zh) 2000-03-29
JPH06503560A (ja) 1994-04-21
CN1128259A (zh) 1996-08-07
CY2005A (en) 1997-12-05
DE69108200D1 (de) 1995-04-20
AP9100339A0 (en) 1992-01-31
GB9126297D0 (en) 1992-02-12
FR2670487A1 (fr) 1992-06-19
YU191491A (sh) 1994-04-05
AU650706B2 (en) 1994-06-30
TW300886B (da) 1997-03-21
GB9026998D0 (en) 1991-01-30
GB2251614B (en) 1994-12-14
FR2670487B1 (fr) 1993-08-20
BE1005085A3 (fr) 1993-04-13
CZ114093A3 (en) 1994-02-16
AP230A (en) 1993-01-27
AU9072091A (en) 1992-07-08
WO1992010477A1 (en) 1992-06-25
JP2994037B2 (ja) 1999-12-27
IS3790A7 (is) 1992-06-13
HK82697A (en) 1997-06-27
ES2069836T3 (es) 1995-05-16
EG20219A (en) 1997-11-30
ZA919750B (en) 1992-10-28
NL9102071A (nl) 1992-07-01
ITRM910922A1 (it) 1993-06-11
PT99757A (pt) 1992-12-31
NZ240942A (en) 1994-03-25
DE69108200T2 (de) 1995-07-20
IE62894B1 (en) 1995-03-08
CH684192A5 (fr) 1994-07-29
CA2098302A1 (en) 1992-06-13
ITRM910922A0 (it) 1991-12-11
CZ281931B6 (cs) 1997-04-16
TW205035B (da) 1993-05-01
ATE119881T1 (de) 1995-04-15
IS1706B (is) 1998-12-10
IE914317A1 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
DK0490689T3 (da) 3-(2-(Dimethylamino)ethyl)-N-methyl-1H-indol-5-methansulfonamid sulfatsalt (2:1)
ITMI930989A0 (it) 3-(carbossimetossifenil)-benzofuran-2-oni come agenti stabilizzanti
DK0443538T3 (da) Bruserhoved
DE69129955D1 (de) Photolackzusammensetzung
DE59107586D1 (de) Beschichtungsmittel
DE69226920D1 (de) Lichtempfindliche Zusammensetzung
BR9100276A (pt) Poco submarino
DE69026835T2 (de) Badesitz
DE69123873T2 (de) Photoresistzusammensetzung
DE69219747D1 (de) Lichtempfindliche Zusammensetzung
IS1605B (is) Botnv”rpuutbunathur
DE69224801D1 (de) Lichtempfindliche Zusammensetzung
MX9100467A (es) 2-(9-fluorenonil)-carbapenem
DE69120858D1 (de) Photoresistzusammensetzung
KR910018729U (ko) 현상기의 닥터 갭 조절장치
KR920011226U (ko) 위생용 상두대
KR920005914U (ko) 샤워기
ITGE910039V0 (it) "boa segna-sub"
SE9001883D0 (sv) Pivaasaengen "nattugglan"
ES1018982Y (es) "braga-compresa"
ES1018426Y (es) "muneco didactico"
ITRE910101U1 (it) "espositore"
ITPE910048V0 (it) "sbossolatrice"
ITPS910048V0 (it) "sbossolatrice"
ITPS910018A1 (it) "sbossolatrice"